On June 6, 2025 Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, reported that the company will host a webcast conference call at 8:00 a.m., ET, on Thursday, June 12, 2025, to discuss new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) that will be presented at the European Hematology Association (EHA) (Free EHA Whitepaper) Congress in Milan, Italy (Press release, Nurix Therapeutics, JUN 6, 2025, https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-host-webcast-conference-call-discuss-data [SID1234653761]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the webcast and conference call are as follows:
Date and time: Thursday, June 12, 8:00 a.m. ET / 2:00 p.m. CEST
Access details: The live webcast will be accessible on the Events page in the Investors section of the company’s website. To participate in the live conference call, the dial-in number in the U.S. is 877-346-6112. For participants outside the U.S., the dial-in number is 1- 848-280-6350. A replay of the webcast and call will be archived on the Nurix website for approximately 30 days after the event.
Details of the presentations at EHA (Free EHA Whitepaper)2025:
Title: Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed refractory CLL: updated findings from an ongoing Phase 1a Study
Presenting author: Talha Munir M.B. Ch.B., Ph.D., Consultant Hematologist at Leeds Teaching Hospitals NHS Trust, Deputy Chair of the United Kingdom National Cancer Research Institute CLL Study Group
Session title: Poster Session 1
Session date and time: Friday, June 13 (18:30 – 19:30 CEST)
Abstract ID: PF571
Title: Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in patients with Waldenström macroglobulinemia
Presenting author: Dima El-Sharkawi, M.B., B.S., M.A., Ph.D., MRCP FRCPath, Consultant Haematologist, Royal Marsden NHS Foundation Trust, Sutton, UK
Session title: Poster Session 2
Session date and time: Saturday, June 14 (18:30 – 19:30 CEST)
Abstract ID: PS1883
About Bexobrutideg (NX-5948)
Bexobrutideg is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK. Bexobrutideg is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies. Additional information on the ongoing clinical trial can be accessed at clinicaltrials.gov (NCT05131022).